Fresh media reports emerged detailing Eli Lilly's discussions with French regulatory officials regarding a potential acquisition of the biotech firm, reigniting earlier rumors from December 10 and sparking renewed investor interest. This built on Abivax's pipeline momentum, particularly its lead candidate obefazimod for ulcerative colitis, which aligns with Lilly's gastrointestinal focus. Trading volume spiked as traders positioned for deal confirmation, amplifying the 15.79% gain during regular market hours. The addition to the Nasdaq Biotechnology Index effective that morning provided minor tailwind but was overshadowed by the acquisition buzz, per financial news outlets.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.